Company History

2021

Clinical study (N=5)

A comparison of peak meal glucose levels in healthy volunteers with or without the administration of A Novel Transdermally Delivered Human Insulin.
2021

Global Reach Potential

InsuLife acquired the global IP for Insulin and diabetes medicine formulation from Transdermal Delivery Solutions Corp. (TDSC).
2020

Clinical and commercial development for insulin initiated by InsuLife AS. 

2018

Clinical Study (N=1)

A Comparison of Injected Insulin Replacement Therapy With A Novel Transdermally Delivered Human Insulin Product.
2017

Insulin was formulated with the Transdermal Delivery System. 

2014

TDS Clinical Study 

A clinical study on Dermal Cumulative Irritation with the TDS® drug delivery system was conducted by The Langford Institute under Dr. Howard Maibach at Dermatology Research Laboratory in San Francisco.
2003 - 2015

Pharmaceutical Drugs Converted to TDS

Several pharmaceutical drugs were formulated and converted to TDS. Development of larger and biological molecules began.
2002

Patent Awarded

The first patent for the Transdermal Delivery System, TDS®, was awarded.
Early 1990s

Transdermal Delivery Research Begins

In the early 1990’s, the CEO of HypoSpray Pharma, Kenneth B. Kirby, began researching ways to improve the safety and efficiency of transdermal drug delivery. He began by investigating which compounds could transmigrate the skin readily and rapidly, without the need to overcome the natural protective barriers of the human skin.
Subscribe for InsuLife News Updates
Sign up to receive the latest InsuLife news, updates and investing information delivered right to your inbox.
InsuLife is a Norwegian company aiming at bringing the unparalleled developmental Levellor™ spray-based insulin to market.
Learn More
© Copyright 2022 - InsuLife AS, All Rights Reserved
licenseenter-down